Azita Saleki-Gerhardt insider trades: AbbVie (ABBV) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Azita reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 12, 2025 | ABBV | ↓ Sell | 42,370 | $198.42 | $8.4M | Direct | Aug 14, 2025 (2d) |
| Feb 21, 2024 | ABBV | ↓ Sell | 52,870 | $173.71 | $9.2M | Direct | Feb 23, 2024 (2d) |
| Mar 1, 2023 | ABBV | ↓ Sell | 36,990 | $154.48 | $5.7M | Direct | Mar 2, 2023 (1d) |
| Feb 17, 2023 | ABBV | ↓ Sell | 25,000 | $149.53 | $3.7M | Direct | Feb 21, 2023 (4d) |
| May 24, 2021 | ABBV | ↓ Sell | 86,920 | $116.29 | $10.1M | Direct | May 26, 2021 (2d) |
| Nov 10, 2020 | ABBV | ↓ Sell | 17,426 | $98.00 | $1.7M | Direct | Nov 12, 2020 (2d) |
| Nov 4, 2020 | ABBV | ↓ Sell10b5-1 | 4,800 | $93.61 | $449K | Direct | Nov 6, 2020 (2d) |
| Mar 5, 2019 | ABBV | ↓ Sell | 15,797 | $79.03 | $1.2M | Direct | Mar 6, 2019 (1d) |
| Feb 28, 2018 | ABBV | ↓ Sell | 1,337 | $117.77 | $157K | Direct | Mar 2, 2018 (2d) |
| Sep 11, 2017 | ABBV | ↓ Sell | 8,300 | $85.02 | $706K | Direct | Sep 12, 2017 (1d) |
| Feb 29, 2016 | ABBV | ↓ Sell | 1,776 | $55.38 | $98K | Direct | Mar 2, 2016 (2d) |
| Feb 27, 2015 | ABBV | ↓ Sell | 2,112 | $60.47 | $128K | Direct | Mar 3, 2015 (4d) |
| Mar 3, 2014 | ABBV | ↓ Sell | 2,443 | $50.25 | $123K | Direct | Mar 4, 2014 (1d) |
| Feb 5, 2014 | ABBV | ↓ Sell | 687 | $47.84 | $33K | Direct | Feb 7, 2014 (2d) |
| Sep 17, 2013 | ABBV | ↓ Sell | 10,473 | $45.84 | $480K | Direct | Sep 18, 2013 (1d) |
| Aug 19, 2013 | ABBV | ↓ Sell | 1,270 | $43.01 | $55K | Direct | Aug 20, 2013 (1d) |
| Aug 12, 2013 | ABBV | ↓ Sell | 8,851 | $44.91 | $397K | Direct | Aug 13, 2013 (1d) |
| Mar 8, 2013 | ABBV | ↓ Sell | 496 | $37.50 | $19K | Direct | Mar 12, 2013 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ABBV insiders
Open-market trades in the last 12 months
About Azita Saleki-Gerhardt's insider trades
Azita Saleki-Gerhardt is EVP, Chief Operations Officer at AbbVie (ABBV). Since Mar 8, 2013, Azita has reported no open-market purchases and 18 sales worth $42.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (1% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (26 filings), shares withheld for taxes (23 filings), option exercises (15 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ABBV insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.